BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab

Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test and build a sustainability framework powered by artificial intelligence for Diamyd Medical’s production facility in Umeå, Sweden.

South Korea’s biotechnology company specializing in molecular diagnostics, Seegene Inc. said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available in Europe.

Orphan Drug Designation for Aspartylglucosaminuria Represents Company’s Third Orphan Designation for a Rare Neurological Disease Lacking Treatment Options

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new pre-recorded fireside chat webcast focused on the company’s eye disease portfolio. Hosted by Cowen, the webcast is intended for investors and other interested parties, and can be accessed at the Johnson & Johnson website www.investor.jnj.c

Neuroglee Therapeutics, which builds personalized evidence-based prescription digital therapeutics for neurodegenerative diseases, has announced its company launch with $2.3 million in pre-seed funding

Protara Therapeutics, Inc. announced the grants of inducement non-qualified stock options to purchase an aggregate of 41,500 shares of common stock to two new employees.

TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually December 5 – 8, 2020.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today highlighted that four abstracts detailing the Company’s clinical trials for Iomab-B and Actimab-A will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually December 5-8, 2020.